Habib Bennaceur: Novo Nordisk Completed its Acquisition of Zaltenibart from Omeros Corporation
Habib Bennaceur, SVP Rare Disease Unit at Novo Nordisk, shared on LinkedIn:
”I am pleased to share that Novo Nordisk completed its acquisition of zaltenibart from Omeros Corporation strengthening our commitment to address unmet needs in rare blood and kidney disorders.
This addition expands our portfolio in haematology and renal as we continue working to serve more people and communities living with rare diseases.
Zaltenibart is an investigational antibody designed to precisely target MASP-3 in the complement system, representing a novel mechanism of action for our haemato-renal portfolio.
Early clinical data in paroxysmal nocturnal haemoglobinuria (PNH) is encouraging, and we look forward to advancing zaltenibart’s development and exploring its potential to provide new treatment options as we drive lasting change in rare disease.”
Stay updated with Hemostasis Today.
-
Jun 9, 2026, 14:13Kayla Garrett: Reducing False Positives and Improving Accuracy in APS
-
Jun 9, 2026, 14:07The Science Behind Bleeding Diathesis and Coagulation Defects – ICHCC
-
Jun 9, 2026, 13:58Kanchi Jain: Delivering Equitable Surgical Care for Women with Advanced Gynecologic Disease
-
Jun 9, 2026, 13:31Mboglen Diane: Why ATLS 11 Places Hemorrhage Control Before Airway Management
-
Jun 9, 2026, 13:20Ifeanyichukwu Ifechidere: The Cell-Based Model of Haemostasis
-
Jun 9, 2026, 13:13James P. Crowley: How Collaboration and Long-Term Research Led to a Nobel Prize–Winning Discovery by Harvey Alter
-
Jun 9, 2026, 13:09Manjot Kaur: Deep Vein Thrombosis Prevention During Long Distance Travel
-
Jun 9, 2026, 11:36Chris Boshoff: FDA Approves Our Treatment for Hemophilia A and B for 2 New Patient Populations
-
Jun 9, 2026, 10:52Vaidehi Prasanth: The Role of Viscoelastic Testing in Low- and Middle-Income Countries